Endo, Vernalis Seek First Triptan Menstrual Migraine Indication With Frova sNDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Frovatriptan sNDA is supported by data from four studies, including two Phase III trials evaluating efficacy in short-term prevention of MM.
You may also be interested in...
Frova Menstrual Migraine Claim Gets Extension
New action date is Sept. 30 for the supplemental indication for frovatriptan, Endo/Vernalis announce.
Frova Menstrual Migraine Claim Gets Extension
New action date is Sept. 30 for the supplemental indication for frovatriptan, Endo/Vernalis announce.
Endo Ketoprofen Patch Fails Two Phase III Studies; Firm Revises 2007 Guidance
Endo awaits results from another Phase III efficacy study expected by Aug. 1 before it makes a go/no go decision on the product.